Cavay Ip

Principal
Cavay Ip_ Life Sciences Strategy_Litigation_ Charles River Associates

Cavay Ip provides expertise in commercialization strategy and pricing and market access strategy to help pharmaceutical and biotech clients achieve their financial and operational goals.

Mr. Ip has developed strategies to launch several market-leading treatments in oncology, immunology, cardiology, and several rare diseases in the U.S. and globally. He has partnered with clients from preclinical/development stage to commercial manufacturers on strategies that help realize the value of their assets and investments.

Mr. Ip also provides financial analysis and valuation assessments in antitrust, litigation, and commercial disputes. In the life sciences industry, he has assessed damages and liability in commercial disputes, intellectual property infringement, and trade secrets misappropriation matters. Beyond the life sciences, Mr. Ip has supported clients with commercial disputes and valuation and financial reporting matters across a range of industries, including technology, nuclear energy, oil and gas, hospitals, airline, retail and consumer products, and the pulp and paper industries.

Selected Engagements

  • 01
    Kowa Co. Ltd. and Livalo ANDA challenge
    Kowa sought a permanent injunction restraining and enjoining Amneal Pharmaceuticals, LLC (Amneal) and Apotex Inc. (Apotex) from infringing on valid Livalo®...
    View engagement
  • 02
    CRA evaluates commercial efforts to develop a MS drug with respect contractual obligations following merger
    CRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...
    View engagement
  • 03
    Dr. Gregory K. Bell opines on commercials success of cholesterol drug
    Kowa sought a permanent injunction restraining and enjoining Amneal Pharmaceuticals, LLC and Apotex Inc. from infringing on valid Livalo® patents through the...
    View engagement

Credentials